Human survivin and Trypanosoma cruzi calreticulin act in synergy against a Murine Melanoma in vivo

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Aguilar Guzmán, Lorena ^a   Lobos González, Lorena ^a   Rosas, Carlos ^a   Vallejos, Gerardo ^a   Falcón, Cristián ^a   Sosoniuk, Eduardo ^a   Coddou, Francisca ^a   Leyton, Lisette ^a   Lemus, David ^a   Quest, Andrew F G ^a   Ferreira, Arturo ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; SURVIVIN; BIRC5 PROTEIN, HUMAN; COMPLEMENT COMPONENT C1Q; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BINDING;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENETIC IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PLASMID; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHAGOCYTOSIS; PROTEIN TERTIARY STRUCTURE; SUBCUTANEOUS TISSUE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CALRETICULIN; CELL LINE, TUMOR; CELL PROLIFERATION; COMPLEMENT C1Q; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; INHIBITOR OF APOPTOSIS PROTEINS; MACROPHAGES; MELANOCYTES; MELANOMA; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SUBCUTANEOUS TISSUE; TRYPANOSOMA CRUZI;

EID: 84899674534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095457     Document Type: Article

References (53)

1. WHO (2014) Cancer. Available: http://www.who.int/mediacentre/factsheets/ fs297/en/index.html. Accessed 2014 April.
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
3. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921. (Pubitemid 27353455)
4. Reed JC, Bischoff JR (2000) BIRinging chromosomes through cell division-and survivin' the experience. Cell 102: 545-548.
5. Reed JC (2001) The Survivin saga goes in vivo. J Clin Invest 108: 965-969.
6. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD (1999) SurvivindeltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102. (Pubitemid 30035627)
7. Pennati M, Folini M, Zaffaroni N (2007) Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139. (Pubitemid 47062670)
8. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
9. Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5: 478-482.
10. Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, et al. (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65: 553-561.
11. Lladser A, Parraga M, Quevedo L, Carmen Molina M, Silva S, et al. (2006) Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology 211: 11-27. (Pubitemid 43150105)
12. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, et al. (2010) Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 24: 665-683.
13. Gelebart P, Opas M, Michalak M (2005) Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 37: 260-266. (Pubitemid 39330186)
14. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M (1999) Calreticulin: one protein, one gene, many functions. Biochem J 344 Pt 2: 281-292. (Pubitemid 30011581)
15. Yokoyama M, Hirata K (2005) New function of calreticulin: calreticul-independent mRNA destabilization. Circ Res 97: 961-963. (Pubitemid 41668907)
16. Mesaeli N, Nakamura K, Zvaritch E, Dickie P, Dziak E, et al. (1999) Calreticulin is essential for cardiac development. J Cell Biol 144: 857-868. (Pubitemid 29238963)
17. Yao L, Pike SE, Tosato G (2002) Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 71: 47-53. (Pubitemid 34062771)
18. Ferreira V, Valck C, Sanchez G, Gingras A, Tzima S, et al. (2004) The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunol 172: 3042-3050. (Pubitemid 38263693)
19. Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, et al. (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94: 2461-2468. (Pubitemid 29467695)
20. Pike SE, Yao L, Jones KD, Cherney B, Appella E, et al. (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188: 2349-2356. (Pubitemid 29028507)
21. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61. (Pubitemid 46067386)
22. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, et al. (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16: 3100-3104.
23. Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, et al. (2011) Heatshock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17: 2474-2483.
24. Eggleton P, Tenner AJ, Reid KB (2000) C1q receptors. Clin Exp Immunol 120: 406-412. (Pubitemid 30365543)
25. Stuart GR, Lynch NJ, Day AJ, Schwaeble WJ, Sim RB (1997) The C1q and collectin binding site within C1q receptor (cell surface calreticulin). Immunopharmacology 38: 73-80. (Pubitemid 28049966)
26. Stuart GR, Lynch NJ, Lu J, Geick A, Moffatt BE, et al. (1996) Localisation of the C1q binding site within C1q receptor/calreticulin. FEBS Lett 397: 245-249. (Pubitemid 26414026)
27. Ghebrehiwet B, Peerschke EI (2004) cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. Mol Immunol 41: 173-183. (Pubitemid 38668627)
28. Sosoniuk E, Vallejos G, Kenawy H, Gaboriaud C, Thielens N, et al. (2014) Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with L-Ficolin. Mol Immunol doi:10.1016/j.molimm.2014.03. 014: In press.
29. Ramirez G, Valck C, Molina MC, Ribeiro CH, Lopez N, et al. (2011) Trypanosoma cruzi calreticulin: a novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Immunobiology 216: 265-273.
30. Valck C, Ramirez G, Lopez N, Ribeiro CH, Maldonado I, et al. (2010) Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol Immunol 47: 1516-1521.
31. Lopez NC, Valck C, Ramirez G, Rodriguez M, Ribeiro C, et al. (2010) Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin. PLoS Negl Trop Dis 4: e730.
32. Molina MC, Ferreira V, Valck C, Aguilar L, Orellana J, et al. (2005) An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. Mol Biochem Parasitol 140: 133-140. (Pubitemid 40332724)
33. Toledo V, Ramirez G, Valck C, Lopez N, Ribeiro CH, et al. (2010) Comparative in vivo antiangiogenic effects of calreticulin from Trypanosoma cruzi and Homo sapiens sapiens. Biol Res 43: 287-289.
34. Sanchez Valdez FJ, Perez Brandan C, Zago MP, Labriola C, Ferreira A, et al. (2013) Trypanosoma cruzi carrying a monoallelic deletion of the calreticulin (TcCRT) gene are susceptible to complement mediated killing and defective in their metacyclogenesis. Mol Immunol 53: 198-205.
35. Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52: 237-268. (Pubitemid 30368433)
36. NRC (1996) Guide for the care and use of laboratory animals. Washington, D.C.: National Academy Press. 125 p.
37. Gabri MR, Mazorra Z, Ripoll GV, Mesa C, Fernandez LE, et al. (2006) Complete antitumor protection by perioperative immunization with GM3/ VSSP vaccine in a preclinical mouse melanoma model. Clin Cancer Res 12: 7092-7098. (Pubitemid 44974509)
38. Aguilar L, Ramirez G, Valck C, Molina MC, Rojas A, et al. (2005) F(ab')2 antibody fragments against Trypanosoma cruzi calreticulin inhibit its interaction with the first component of human complement. Biol Res 38: 187-195. (Pubitemid 41535619)
39. Marcelain K, Colombo A, Molina MC, Ferreira L, Lorca M, et al. (2000) Development of an immunoenzymatic assay for the detection of human antibodies against Trypanosoma cruzi calreticulin, an immunodominant antigen. Acta Trop 75: 291-300. (Pubitemid 30320866)
40. Aguillon JC, Harris R, Molina MC, Colombo A, Cortes C, et al. (1997) Recognition of an immunogenetically selected Trypanosoma cruzi antigen by seropositive chagasic human sera. Acta Trop 63: 159-166. (Pubitemid 27148045)
41. Ramos R, Juri M, Ramos A, Hoecker G, Lavandero S, et al. (1991) An immunogenetically defined and immunodominant Trypanosoma cruzi antigen. Am J Trop Med Hyg 44: 314-322.
42. Ramirez G, Valck C, Aguilar L, Kemmerling U, Lopez-Munoz R, et al. (2012) Roles of Trypanosoma cruzi calreticulin in parasite-host interactions and in tumor growth. Mol Immunol 52: 133-140.
43. Castillo C, Ramirez G, Valck C, Aguilar L, Maldonado I, et al. (2013) The Interaction of Classical Complement Component C1 with Parasite and Host Calreticulin Mediates Trypanosoma cruzi Infection of Human Placenta. PLoS Negl Trop Dis 7: e2376.
44. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, et al. (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49. (Pubitemid 28028045)
45. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, et al. (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96: 1921-1925. (Pubitemid 30661078)
46. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, et al. (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111: 196-203.
47. Altieri DC (2008) New wirings in the survivin networks. Oncogene 27: 6276-6284.
48. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, et al. (2010) Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 59: 81-92.
49. Ferreira V, Molina MC, Valck C, Rojas A, Aguilar L, et al. (2004) Role of calreticulin from parasites in its interaction with vertebrate hosts. Mol Immunol 40: 1279-1291. (Pubitemid 38210266)
50. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
51. White TK, Zhu Q, Tanzer ML (1995) Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem 270: 15926-15929.
52. Morley BJ, Walport MJ (2000) The Complement FactsBook. London, UK: Academic Press. 228 p.
53. Liu X, Xu N, Zhang S (2013) Calreticulin is a microbial-binding molecule with phagocytosis-enhancing capacity. Fish Shellfish Immunol 35: 776-784.